Literature DB >> 6891260

In vitro cytotoxic drug sensitivity testing of human tumour xenografts grown as multicellular tumour spheroids.

A C Jones, I J Stratford, P A Wilson, M J Peckham.   

Abstract

Tumour cells from 7 patients with ovarian carcinoma and from 22 different human tumour xenografts representing a wide range of histological sub-types have been examined for multicellular spheroid forming ability. Spheroid formation was limited to cells derived from xenografts. Of the 22 lines tested, 5 formed spheroids capable of growth in isolation. There was no clear relationship between histological type and spheroid-forming ability. The plating efficiency of tumour cells obtained from spheroids was always greater than for the cells obtained from the dissociated tumour of origin and was in some cases as much as 6-fold greater. Spheroid growth was nearly exponential for 4 cell lines. Volume growth delay was used to investigate the activity of melphalan, adriamycin, the Vinca alkaloids, CCNU and cisplatin. Differences between lines in drug response broadly reflected patient and in vivo xenograft response.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6891260      PMCID: PMC2011214          DOI: 10.1038/bjc.1982.296

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Repair and reoxygenation following irradiation of an in vitro tumor model.

Authors:  R E Durand; R M Sutherland
Journal:  Int J Radiat Oncol Biol Phys       Date:  1976 Nov-Dec       Impact factor: 7.038

2.  Proliferation and viability in cellular spheroids of human origin.

Authors:  M Haji-Karim; J Carlsson
Journal:  Cancer Res       Date:  1978-05       Impact factor: 12.701

3.  Ectopic hormone production by bronchial carcinomas in culture.

Authors:  M L Ellison; C J Hillyard; G A Bloomfield; L H Rees; R C Coombes; A M Neville
Journal:  Clin Endocrinol (Oxf)       Date:  1976       Impact factor: 3.478

4.  Growth of multicell spheroids in tissue culture as a model of nodular carcinomas.

Authors:  R M Sutherland; J A McCredie; W R Inch
Journal:  J Natl Cancer Inst       Date:  1971-01       Impact factor: 13.506

5.  In vitro analysis of the response of multicellular tumor spheroids exposed to chemotherapeutic agents in vitro or in vivo.

Authors:  J M Yuhas; A E Tarleton; J G Harman
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

6.  Growth fraction as the major determinant of multicellular tumor spheroid growth rates.

Authors:  J M Yuhas; A P Li
Journal:  Cancer Res       Date:  1978-06       Impact factor: 12.701

7.  Multicellular tumor spheroid formation by breast cancer cells isolated from different sites.

Authors:  J M Yuhas; A E Tarleton; K B Molzen
Journal:  Cancer Res       Date:  1978-08       Impact factor: 12.701

8.  A soft agar colony assay for Lewis lung tumour and B16 melanoma taken directly from the mouse.

Authors:  V D Courtenay
Journal:  Br J Cancer       Date:  1976-07       Impact factor: 7.640

9.  Variation in response of xenografts of colo-rectal carcinoma to chemotherapy.

Authors:  K Nowak; M J Peckham; G G Steel
Journal:  Br J Cancer       Date:  1978-04       Impact factor: 7.640

10.  Improved immune-suppression techniques for the exongrafting of human tumours.

Authors:  G G Steel; V D Courtenay; A Y Rostom
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

View more
  12 in total

1.  Cell proliferation in human tumours growing in nude mice: renal cell carcinomas, larynx and hypopharynx carcinomas.

Authors:  B Maurer-Schultze; I D Bassukas; M Böswald; M Harasim
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. II. Assay methods, adriamycin and the other antitumour antibiotics.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids.

Authors:  R C Casey; K M Burleson; K M Skubitz; S E Pambuccian; T R Oegema; L E Ruff; A P Skubitz
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

4.  Inhibition of protein synthesis, pulmonary localization and pulmonary tumour formation by drug-treated tumour cells as a means of predicting their chemosensitivity.

Authors:  T Lai; B R Stonebridge; J Black; M O Symes
Journal:  Clin Exp Metastasis       Date:  1989 Jul-Aug       Impact factor: 5.150

5.  Tumour fragment spheroids from human non-small-cell lung cancer maintained in organ culture.

Authors:  L Fjellbirkeland; R Bjerkvig; O D Laerum
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs.

Authors:  Justin C Jagodinsky; Agnieszka Sulima; Yiqi Cao; Joanna E Poprawski; Burchelle N Blackman; John R Lloyd; Rolf E Swenson; Michael M Gottesman; Matthew D Hall
Journal:  J Biol Inorg Chem       Date:  2015-09-01       Impact factor: 3.358

Review 7.  Multicellular spheroids. A review on cellular aggregates in cancer research.

Authors:  W Mueller-Klieser
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

8.  Clonogenicity of mammalian cells in hybrid spheroids: a new assay method.

Authors:  B Djordjevic; C S Lange
Journal:  Radiat Environ Biophys       Date:  1990       Impact factor: 1.925

9.  Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells.

Authors:  D L Roberts; K J Williams; R L Cowen; M Barathova; A J Eustace; S Brittain-Dissont; M J Tilby; D G Pearson; C J Ottley; I J Stratford; C Dive
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

10.  Growth and radiation sensitivity of the MLS human ovarian carcinoma cell line grown as multicellular spheroids and xenografted tumours.

Authors:  E K Rofstad; R M Sutherland
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.